Assuming approval, in which patients would you choose Belzutifan + Lenvatinib (LITESPARK-011) for advanced RCC, with progression after IO therapy?

LITESPARK-011 is an interesting study as it relates to current standard practice. Presently, lenvatinib/everolimus is a well-established and potent treatment option. Each clearly contributes towards the clinical benefit observed in most patients. For instance, in the study NCT01136733 (Motzer et al....